MCManabu Chokki

Manabu Chokki

*This is an algorithmically generated author record based on publicly available information.

Manabu Chokki has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Takashi Kamimura

    Bio-medical Evaluation Research Department, Pharmaceutical Discovery Research Laboratories, Teijin Pharma Limited, 4-3-2, Asahigaoka, Hino, Tokyo 191-8512, Japan

    3 shared publications
  • Hiroaki Mitsuhashi

    Bio-medical Evaluation Research Department, Pharmaceutical Discovery Research Laboratories, Teijin Pharma Limited, 4-3-2, Asahigaoka, Hino, Tokyo 191-8512, Japan

    2 shared publications
  • Hiroshi Eguchi

    Pharmaceutical Discovery Research Laboratories, Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo, Japan

    2 shared publications
  • Hideki Horiuchi

    Pharmacological Research Department, Teijin Institute for Bio-Medical Research, Teijin Limited, Tokyo; and Department of Nutrition, University of Tokushima School of Medicine, Tokushima City, Japan

    1 shared publication
  • Hirofumi Tanabe

    Pharmacological Research Department, Teijin Institute for Bio-Medical Research, Teijin Limited, Tokyo; and Department of Nutrition, University of Tokushima School of Medicine, Tokushima City, Japan

    1 shared publication
  • Ichiro Hamamura

    Pharmaceutical Discovery Research Laboratories, Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo, Japan

    1 shared publication

Latest Publications

  • Open Access

    Human airway trypsin‐like protease induces amphiregulin release through a mechanism involving protease‐activated receptor‐2‐mediated ERK activation and TNF α‐converting enzyme activity in airway epithelial cells

    by Manabu Chokki, Hiroshi Eguchi, Ichiro Hamamura, Hiroaki Mitsuhashi, Takashi Kamimura

    Human airway trypsin‐like protease (HAT), a serine protease found in the sputum of patients with chronic airway diseases, is an agonist of protease‐activated receptor‐2 (PAR‐2). Previous results have shown that HAT enhances the release of amphiregulin (AR); further, it causes MUC5AC gene expression through the AR‐epidermal growth factor receptor pathway in the airway epithelial cell line NCI‐H292. In this study, the mechanisms by which HAT‐induced AR release can occur were investigated. HAT‐induced AR gene expression was mediated by extracellular signal‐regulated kinase (ERK) pathway, as pretreatment of cells with ERK pathway inhibitor eliminated the effect of HAT on AR mRNA. Both HAT and PAR‐2 agonist peptide (PAR‐2 AP) induced ERK phosphorylation; further, desensitization of PAR‐2 with a brief exposure of cells to PAR‐2 AP resulted in inhibition of HAT‐induced ERK phosphorylation, suggesting that HAT activates ERK through PAR‐2. Moreover, PAR‐2 AP induced AR gene expression subsequent to protein production in the cellular fraction through the ERK pathway indicating that PAR‐2‐mediated activation of ERK is essential for HAT‐induced AR production. However, in contrast to HAT, PAR‐2 AP could not cause AR release into extracellular space; it appears that activation of PAR‐2 is not sufficient for HAT‐induced AR release. Finally, HAT‐induced AR release was eliminated by blockade of tumour necrosis factor α‐converting enzyme (TACE) by the TAPI‐1 and RNA interference, suggesting that TACE activity is necessary for HAT‐induced AR release. These observations show that HAT induces AR production through the PAR‐2 mediated ERK pathway, and then causes AR release by a TACE‐dependent mechanism.


  • Human Airway Trypsin-Like Protease Increases Mucin Gene Expression in Airway Epithelial Cells

    by Manabu Chokki, Satoshi Yamamura, Hiroshi Eguchi, Tsukio Masegi, Hideki Horiuchi, Hirofumi Tanabe, Takashi Kamimura, Susumu Yasuoka

    Human airway trypsin-like protease (HAT) is a serine protease found in sputum of patients with chronic airway diseases and is an agonist of protease-activated receptor-2 (PAR-2). Results from this study show that HAT treatment also enhances mucus production by the airway epithelial cell line NCI-H292 in vitro. Histologic examination showed that HAT enhances mucous glycoconjugate synthesis, whereas the PAR-2 agonist peptide (PAR-2 AP) has no such effect. HAT, but not PAR-2 AP, enhances MUC2 and MUC5AC gene expression 23-fold and 32-fold, respectively. The proteolytic activity of HAT is required to enhance MUC5AC gene expression; the addition of the inhibitors of trypsin-like protease activity of HAT, aprotinin and leupeptin, abolishes its enhancing effect. AG1478, anti-epidermal growth factor receptor (anti-EGFR)–neutralizing antibody, and anti-amphiregulin (AR)-neutralizing antibody all inhibited the stimulatory effect of HAT. Furthermore, HAT increases AR gene expression and subsequent AR protein release, whereas PAR-2 AP shows no such effects. These results indicate that HAT enhances mucin gene expression through an AR-EGFR pathway, and PAR-2 is not sufficient for or does not directly cause HAT-induced mucin gene expression. Thus, HAT might be a possible therapeutic target to prevent excessive mucus production in patients with chronic airway diseases.